SCHEMBL15072064

SCHEMBL15072064

CN1CCCC1CNc1nc(Nc2cnn(C)c2)ncc1Cl

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK19 Q9BWU1 1/20 0.56
ALK Q9UM73 1/20 0.56
KDR P35968 5/20 0.53
AURKB Q96GD4 5/20 0.53
JAK1 P23458 9/20 0.53
JAK2 O60674 8/20 0.53
JAK3 P52333 3/20 0.51
AURKA O14965 6/20 0.50
TYK2 P29597 2/20 0.50
FLT3 P36888 2/20 0.50
CDC7 O00311 1/20 0.50
DAPK3 O43293 1/20 0.50
ROCK2 O75116 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
PAK4 O96013 1/20 0.50
PIM1 P11309 1/20 0.50
PRKACA P17612 1/20 0.50
CDK2 P24941 1/20 0.50
SYK P43405 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15059182 0.90 CDK19 (0.53) CDK19ALKKDRAURKBJAK1
SCHEMBL15059962 0.90 CDK19 (0.53) CDK19ALKKDRAURKBJAK1
SCHEMBL15058533 0.90 CDK19 (0.53) CDK19ALKKDRAURKBJAK1
SCHEMBL15059872 0.89 CDK19 (0.52) CDK19ALKKDRAURKBJAK1
SCHEMBL15060142 0.88 CDK19 (0.51) CDK19ALKKDRAURKBJAK1
SCHEMBL16337254 0.88 CDK19 (0.51) CDK19ALKKDRAURKBJAK1
SCHEMBL15059253 0.87 JAK1 (0.56) CDK19ALKKDRAURKBJAK1
SCHEMBL15059061 0.87 JAK1 (0.56) CDK19ALKKDRAURKBJAK1
SCHEMBL15059487 0.87 JAK1 (0.56) CDK19ALKKDRAURKBJAK1
SCHEMBL15071798 0.87 JAK1 (0.56) CDK19ALKKDRAURKBJAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2015-01-01 US claimed
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2015-01-01 US disclosed
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2015-01-01 US disclosed
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2015-01-01 US disclosed
WO-2013092854-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS CELLZOME LIMITED (GB) 2013-06-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150005281-A1 PYRIMIDINE-2,4-DIAMINE DERIVATIVES AS KINASE INHIBITORS JAK2, JAK1, JAK3 CDK19 98/4885ALK 1042/4885KDR 2835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.